Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Beard gains from minoxidil are usually permanent due to facial hair follicles' lower sensitivity to DHT. Scalp hair requires ongoing DHT suppression with treatments like finasteride, dutasteride, and RU58841 to maintain gains after stopping minoxidil.

A 26-year-old is experiencing hair loss despite using minoxidil and dutasteride. Suggestions include shaving his head, trying oral minoxidil, or considering a hair transplant.

The user is concerned about having a straight, low hairline after a hair transplant and is unable to take finasteride due to high estrogen and prolactin levels. They have used minoxidil with limited success and are considering further transplants to lower the hairline, while others suggest the risks of using up donor hair too quickly.

Finasteride changed the user's hair texture from wavy to curly, reverting after stopping. Minoxidil was more effective for temple hair regrowth than finasteride.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

Diet and lifestyle changes can reduce hair shedding but won't regrow hair lost to genetic male pattern baldness. Treatments like finasteride and dutasteride are necessary for significant hair regrowth.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The person experienced worsening hair loss despite using minoxidil, finasteride, and dutasteride. They are considering increasing dutasteride dosage, trying microneedling, RU58841, and oral minoxidil, and are advised to consult a trichologist.